Amring Pharmaceuticals has acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc.  Acquired ANDAs include niche otic and ophthalmic pharmaceuticals that will bring value to customers and patients.

Daniel Carbery, President of Amring, stated, "We are pleased with our progress during the past year and look forward to realizing the benefits of our business development activities in 2017.  On March 1, we completed our acquisition of six ANDAs.  Along with several other products in our internal development pipeline, these products provide us with an opportunity to compete in a growing market for niche otic and ophthalmic generic drugs.  Amring intends to start marketing and distributing these products in the United States in the coming months."